Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6047211 | 0.92 | ADORA2A (0.55) | ALDH1A1ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL6047319 | 0.85 | ADORA2A (0.60) | NPC1ALDH1A1RAB9ASMN1; SMN2ADORA2A | |
| SCHEMBL6047294 | 0.85 | ADORA2A (0.55) | NPC1RAB9AADORA2AADORA3ADORA2B | |
| SCHEMBL6047383 | 0.83 | KDM4E (0.56) | NPC1ALDH1A1HPGDRAB9AADORA2A | |
| SCHEMBL6047187 | 0.82 | ADORA2A (0.61) | ADORA2A | |
| SCHEMBL6047201 | 0.82 | ADORA2A (0.50) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL6047175 | 0.81 | ADORA2A (0.66) | ADORA2A | |
| SCHEMBL6047332 | 0.81 | ADORA2A (0.64) | NPC1ALDH1A1HPGDADORA2AADORA3 | |
| SCHEMBL6047304 | 0.80 | ADORA2A (0.58) | ADORA2A | |
| SCHEMBL6870605 | 0.79 | ADORA2A (0.58) | ALDH1A1HPGDADORA2AADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058320-A1 | [1,2,4] Triazolo[1,5-c]pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-16 | — | — | US | disclosed |
| EP-1544200-A1 | 1,2,4 -TRIAZOLO 1,5-c PYRIMIDINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058320-A1 | [1,2,4] Triazolo[1,5-c]pyrimidine derivatives | ADORA2A, ADORA1, ADORA3 | NPC1 1940/4885ALDH1A1 360/4885LMNA 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.